| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CYP2A13 |
| Uniprot No | Q16696 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-494aa |
| 氨基酸序列 | MLASGLLLVTLLACLTVMVLMSVWRQRKSRGKLPPGPTPLPFIGNYLQLNTEQMYNSLMKISERYGPVFTIHLGPRRVVVLCGHDAVKEALVDQAEEFSGRGEQATFDWLFKGYGVAFSNGERAKQLRRFSIATLRGFGVGKRGIEERIQEEAGFLIDALRGTHGANIDPTFFLSRTVSNVISSIVFGDRFDYEDKEFLSLLRMMLGSFQFTATSTGQLYEMFSSVMKHLPGPQQQAFKELQGLEDFIAKKVEHNQRTLDPNSPRDFIDSFLIRMQEEEKNPNTEFYLKNLVMTTLNLFFAGTETVSTTLRYGFLLLMKHPEVEAKVHEEIDRVIGKNRQPKFEDRAKMPYTEAVIHEIQRFGDMLPMGLAHRVNKDTKFRDFFLPKGTEVFPMLGSVLRDPRFFSNPRDFNPQHFLDKKGQFKKSDAFVPFSIGKRYCFGEGLARMELFLFFTTIMQNFRFKSPQSPKDIDVSPKHVGFATIPRNYTMSFLPR |
| 预测分子量 | 64.1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
1. **"Functional characterization of recombinant human CYP2A13 in the metabolism of nicotine and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK)" by Zhang et al.**
该研究通过表达重组CYP2A13蛋白，揭示了其在尼古丁和烟草特异性致癌物NNK代谢中的高效催化活性，强调了其在呼吸道毒性及肺癌发生中的潜在作用。
2. **"Expression and catalytic activity of human cytochrome P450 CYP2A13 in Escherichia coli: Role in bioactivation of nasal toxicants" by Su et al.**
作者利用大肠杆菌系统成功表达重组CYP2A13.证明其能高效代谢鼻腔吸入的芳香类致癌物(如1.3-丁二烯)，提示其在鼻咽部化学物质致毒机制中的关键功能。
3. **"Genetic polymorphisms of CYP2A13 and its impact on nicotine metabolism in vitro" by Wang et al.**
研究通过重组CYP2A13蛋白分析不同基因多态性对酶活性的影响，发现某些突变体显著降低尼古丁氧化效率，为个体烟草相关疾病易感性差异提供了分子依据。
4. **"Comparative metabolism of aflatoxin B1 by recombinant CYP2A13 and CYP1A2: Implications for respiratory exposure risk" by Li et al.**
该文献对比重组CYP2A13与CYP1A2对黄曲霉毒素B1的代谢能力，发现CYP2A13在肺组织中可能主导其活化生成致癌中间体，提示其作为呼吸道暴露生物标志物的潜力。
CYP2A13 is a cytochrome P450 enzyme primarily expressed in the human respiratory tract, olfactory mucosa, and other extrahepatic tissues. As a member of the CYP2A subfamily within the CYP450 superfamily, it plays a critical role in metabolizing xenobiotics, including tobacco-specific nitrosamines like N'-nitrosonornicotine (NNK), and certain pharmaceuticals. Unlike its hepatic counterpart CYP2A6. CYP2A13 exhibits high catalytic efficiency in activating procarcinogens, contributing to its association with tissue-specific chemical toxicity and carcinogenesis, particularly in tobacco-related lung cancers. However, its low natural abundance and tissue-specific localization make studying its native form challenging.
Recombinant CYP2A13 protein is produced using heterologous expression systems (e.g., Escherichia coli, yeast, or mammalian cells) to enable detailed biochemical and toxicological analyses. Researchers often co-express it with NADPH-cytochrome P450 reductase to reconstitute enzymatic activity in vitro. This engineered protein allows for mechanistic studies on substrate metabolism, enzyme kinetics, and genetic polymorphisms affecting function. Its applications span toxicology (evaluating chemical bioactivation), pharmacology (drug metabolism prediction), and cancer research (elucidating molecular pathways in chemical carcinogenesis). Additionally, recombinant CYP2A13 aids in screening inhibitors or modulators for therapeutic or chemopreventive strategies. Despite its utility, challenges persist in maintaining structural stability and catalytic activity during purification, requiring optimization of expression conditions and protein engineering approaches. Current research continues to refine production methods while exploring its role in interindividual susceptibility to environmental toxins and respiratory diseases.
×
